Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis––experiences from recent clinical trials

Aller, S. Paredes; Quittner, Alexandra L.; Salathé, Matthias; Schmid, Andreas

doi:10.1080/17476348.2018.1503540

Cited by 16 publications

(9 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NCFB results from a permanent and progressive destruction of the airways leading to poor lung function, and is characterized by recurrent lung infection. Patients with NCFB and chronic infections with P. aeruginosa have a high risk of hospitalization, reduced quality of life, and increased mortality [23]. Current guidelines recommend inhaled tobramycin for individuals with CF and persistent P. aeruginosa infection who are aged 6 years or older [24].…”

Section: Inhaled Treatment For Acute and Chronic Infections And Possimentioning

confidence: 99%

Inhaled Liposomal Antimicrobial Delivery in Lung Infections

Bassetti

Vena

Russo

et al. 2020

Drugs

View full text Add to dashboard Cite

The management of difficult-to-treat acute and chronic respiratory infections (infections in cystic fibrosis, non-cystic fibrosis bronchiectasis, immunocompromised and mechanically ventilated patients) and difficult-to-treat pathogens (including multidrug-resistant strains) has become a challenge in clinical practice. The arsenal of conventional antibiotic drugs can be limited by tissue penetration, toxicities, or increasing antibiotic resistance. Inhaled antimicrobials are an interesting therapeutic approach for optimizing the management of respiratory infections. Due to extensive developments in liposome technology, a number of inhaled liposome-based antibiotic and antifungal formulations are available for human use and many products are undergoing clinical trials. Liposomes are biocompatible, biodegradable, and nontoxic vesicles able to encapsulate and carry antimicrobials, enhancing the therapeutic index of various agents and retention at the desired target within the lung. Liposomes reduce drug toxicity and improve tolerability, leading to better compliance and to decreased respiratory side effects. The aim of this article was to provide an up-to-date overview of nebulized liposomal antimicrobials for lung infections (with a special focus on liposomal amikacin, tobramycin, ciprofloxacin, and amphotericin B for inhalation), discussing the feasibility and therapeutic potential of these new strategies of preventing and treating bacteria, mycobacterial and fungal infections.

show abstract

Section: Inhaled Treatment For Acute and Chronic Infections And Possimentioning

confidence: 99%

Inhaled Liposomal Antimicrobial Delivery in Lung Infections

Bassetti

Vena

Russo

et al. 2020

Drugs

View full text Add to dashboard Cite

show abstract

“…Однако серьезной проблемой ингаляционной АБТ является возврат плотности бактериальной нагрузки P. aeruginosa в мокроте к исходным значениям спустя короткое время (от нескольких дней до 3 мес.) после завершения курса эффективной терапии [47].…”

Section: ингаляционные антибактериальные препаратыunclassified

“…Ни один из ингаляционных АБП -колистин, ципрофлоксацин, гентамицин и тобрамицин -не влиял на легочную функцию и газовый состав артериальной крови [47].…”

Section: ингаляционные антибактериальные препаратыunclassified

“…На сегодняшний день ни один ингаляционный АБП не имеет официального разрешения к применению при немуковисцидозных БЭ ни в США, ни в странах Европы [47].…”

Section: эффекты ингаляционных антибактериальных препаратов и длительunclassified

See 1 more Smart Citation

Current approaches to pharmacological treatment of adult patients with bronchiectasis

Чикина

Авдеев

2019

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Бронхоэктазы (БЭ)-это хроническое бронхолегочное заболевание, которое характеризуется кашлем, продукцией мокроты и рецидивирующей бронхиальной инфекцией, а также патологической дилатацией бронхов при рентгеновском исследовании. БЭ могут сопровождать множество разнообразных заболеваний и патологических состояний. Дилатация бронхов может возникать при первичном структурном дефекте бронхиальной стенки, патологическом повышении давления внутри бронха или

show abstract

“…Owing to the limited study evidence, inhaled antibiotics are not currently approved for treating NCFB by the U.S. Food and Drug Administration and the European Medicines Agency. (7) This study was conducted to evaluate the results of patients with NCFB receiving inhaled tobramycin for PA colonization after obtaining approval from the Turkish Ministry of Health for nonindicative drug use.…”

Section: Introductionmentioning

confidence: 99%

Results of Tobramycin Inhalation Therapy in Patients with Noncystic Fibrosis Bronchiectasis with Pseudomonas aeruginosa Colonization: Real Life Management

Tanrıverdi

Yıldırım

Gul

et al. 2021

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

Background: Inhaled antibiotics for treating bronchiectasis have been investigated in the cystic fibrosis population since 1981 and long-term clinical benefits have been reported. However, studies on noncystic fibrosis bronchiectasis (NCFB) have only been performed more recently. Owing to limited evidence, inhaled antibiotics are not currently approved for treating NCFB by the U.S. Food and Drug Administration and the European Medicines Agency. The aim of this study was to evaluate the efficacy and safety of tobramycin inhalation therapy in patients with bronchiectasis with Pseudomonas aeruginosa (PA) colonization. Methods: In this retrospective cross-sectional study, NCFB patients who were Pseudomonas positive on three consecutive cultures 1 month apart and receiving tobramycin inhalation therapy were evaluated. Evaluation of the following parameters was done in this study: age, gender, smoking history, symptoms, pulmonary function test results, sputum culture results, tobramycin treatment duration, side effects of tobramycin and response evaluation, and hospital admissions before and after treatment. Treatment with 300 mg tobramycin through nebulizer twice daily for 28 days on-off cycles for a total of 6 months was considered to be one treatment period. The approvals for the study were received by the local ethics committee and institutional review board. Results: Of the 27 patients, 21 patients completed the first period, 7 patients completed the second period, 4 patients completed the third period, and 1 patient completed the fourth period. Sputum culture was negative in 10 (47.6%) of the 21 patients who completed the first period. Decreased sputum purulence and quantity, dyspnea, and cough were observed during treatment. The frequency of hospitalizations before treatment was 1.24-1.36, whereas after treatment, it decreased to 0.52-0.91, this difference was statistically significant (p ¼ 0.019). The most common side effect was increased dyspnea after nebulization in five patients. Conclusion: Tobramycin inhalation appears to be a well-tolerated treatment in patients with PA colonization with bronchiectasis. This treatment may decrease the hospitalization rates and improve the symptoms.

show abstract

Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis––experiences from recent clinical trials

Cited by 16 publications

References 77 publications

Inhaled Liposomal Antimicrobial Delivery in Lung Infections

Inhaled Liposomal Antimicrobial Delivery in Lung Infections

Current approaches to pharmacological treatment of adult patients with bronchiectasis

Results of Tobramycin Inhalation Therapy in Patients with Noncystic Fibrosis Bronchiectasis with Pseudomonas aeruginosa Colonization: Real Life Management

Contact Info

Product

Resources

About